Men's News
OncoLink Cancer Resource Home

 
OncoLink Cancer Resource Home

Men's News

OncoLink Cancer Resource Home
Types of Cancer Home
OncoLink Cancer Resource
Cancer Treatment Information Physician List
OncoLink Cancer Resource
Coping with Cancer MCC Staff
OncoLink Cancer Resource
Cancer Clinical Trials Matching Service Provider News
OncoLink Cancer Resource
Cancer Resources and News Women's News
OncoLink Cancer Resource
Ask the Cancer Experts Men's News
OncoLink Cancer Resource
OncoLink Cancer Library Treatment Protocols
OncoLink Cancer Resource
Cancer and Oncology Sponsors Cancer Control Protocols
OncoLink Cancer Resource
Giving to Oncolink's Cancer Resources Radiation Oncology
About Oncolink's Cancer Resources Upcoming Protocols
OncoLink
Giving to Oncolink's Cancer Resources Closed Protocols
Giving to Oncolink's Cancer Resources Related Links
Oncolink Cancer Resource Home
 


 

 
[SELECT logo]

  Montana Cancer Consortium is participating in the National Cancer Institute cancer prevention trial - SELECT.  More than 32,000 men are participating in SELECT from the United States, Canada, and Puerto Rico.  This 12-year study is trying to determine if taking selenium and/or vitamin E can prevent prostate and other cancers.  These volunteers have helped to set a new pace for recruitment to clinical trials.  This largest-ever prostate cancer prevention trial began enrollment in August, 2001.  It was expected to take 5 years to recruit the 32,400 men needed to complete the study.  SELECT recruitment exceeded this total in less than 3 years.

 click here for: SELECT   SWOG website       MEN FIGHTING TO PREVENT PROSTATE CANCER

Click Here for the National Institutes of Health website on Prostate Cancer (click "next page" 4 times for link to SELECT video)

Click Here for prostate cancer information     www.fightprostatecancer.org

 

 

Researchers find red wine can reduce risk of prostate cancer

 by Rosanne Fohn, Communications Coordinator, Southwest Oncology Group

      Wouldn’t it be nice if something as simple as a glass of wine could help prevent prostate cancer?  That’s what a study from the International Journal of Cancer suggests.                                                                           “We found that men who consumed four or more glasses of red wine per week reduced their risk of prostate cancer by 50%,” said Janet L. Stanford, Ph.D.  Stanford is senior author of “Alcohol consumption and risk of  prostate cancer in middle-aged men”.  The study appeared in the September 2004 edition of the journal.                                                                               Red wine seemed to be most effective in preventing aggressive types of cancer, Stanford said.  Researchers found about 60 percent fewer cases of the aggressive types of cancer in men who drank four or more 4-ounce glasses of wine a week.  Stanford’s comments come from a press release issued by the Fred Hutchinson Cancer Research Center where the study was conducted.                                                                          Dr. Scott Lippman, Study Coordinator for the Selenium and Vitamin E Cancer Prevention Trial (SELECT), discussed the red wine study at the Fall 2004 Southwest Oncology Group Meeting.  “This is one of only a few studies that show a strong connection between drinking liquor and the prevention of prostate cancer,” he said.  “This is a small study.  While the results are preliminary they do show some promise, especially if other studies confirm the results.”           The study compared red wine, white wine, beer and hard liquor, but only red wine seemed to prevent cancer.  Researchers think the beneficial ingredient in red wine is resveratrol.  There are high levels of resveratrol in the skin of red grapes.  Smaller amounts also are found in white grapes, peanuts, and raspberries.                                                                         The study showed that the chance of prostate cancer went down 6 % with each glass of red wine the men drank during a given week.  However, the results were not as positive when the men drank more than a moderate amount of red wine.  Stanford said that it is hard to encourage people to drink more than a small amount of alclhol because of problems that can come from heavy drinking.  These problems can include a higher overall risk of cancer, the chance of an injury and social problems.                                                       “But for men who already are consuming alcohol, I think the results of this study suggest that modest consumption of red wine, about for to eight 4-ounce drinks per week, is the level at which you might receive benefit.  Clearly other studies show that more than that may have adverse effects on your health.”

 

What is resveratrol?  

According to the National Cancer Institute (NCI) resveratrol is a type of antioxidant compound found in grape skins and seeds.  This compound helps the grapevine defend itself against disease, infection, stress, and injury.                                              Red wine contains higher levels of resveratrol than white wine.  When white wine is made, the grape skins are removed after the grapes are crushed.  This is not the case when red wine is made.  When the red wine ferments, the antioxidant compounds from both the skin and the seeds become concentrated in the wine.                                                       Scientists are still in the early  stages of testing the effects of red wine on cancer in humans.  The types of cancer being studied include leukemia, skin, breast and prostate cancer.                          The NCI cautions that drinking large amounts of alcoholic beverages may increase the overall risk of some types of cancer.           

 

 

 

 

 
Updated 6/25/2008

Prostate Cancer Prevention

Prostate Cancer Treatment

Prostate Cancer Risks

Other Helpful Websites

 

 

Confused by Prostate Cancer Treatment Options

There is little good research directly comparing prostate cancer treatment options to help the newly diagnosed choose between surgery, two types of radiation, or watching a small tumor to see if it needs treating at all.  Two new studies suggest the advice gap has consequences:  over-treating early-stage tumors, and therapy choices driven by fear and misconceptions. 

Not all prostate cancer is the same.  Certainly aggressive prostate cancer can kill, but often, prostate cancer is so slow-growing, and discovered when it's so small, that men will die of something else before it ever causes symptoms, much less becomes life-threatening.    One man in every six will get prostate cancer, but only one in 34 will die of it, according to the American Cancer Society.   That sounds reassuring until you're the man wondering if you'll be in the lucky majority or not.  Unfortunately, doctors have no easy way to tell.

Many studies are contradictory and there are no newer studies comparing the more modern surgical and radiation techniques.  So doctors typically just present all the options and let men choose.

If you are faced with making a decision about your treatment for prostate cancer, click on the website link above for comparisons of the various treatments and scientific data available.

Michigan Cancer Consortium /Washington (AP)

OncoLink Cancer Resource Home